avalon-globocare.com (ALBT) Long-Term Debt to Capital Coefficient

Clinics and laboratories provide a stable cash flow for Avalon GloboCare (ALBT), although biotech projects are not yet generating profit. The long-term debt-to-equity ratio helps assess the balance sheet, where the current level is 0.01. Demand for cell therapy remains independent of economic cycles, while the company's environmental policy is based on the digitalization of archives and the safe disposal of biomaterials.

This metric compares the volume of liabilities with a maturity exceeding one year against the organization's total net equity. It determines the extent to which long-term financing depends on internal resources to assess solvency. For the laboratory diagnostics and cell therapy ecosystem of Avalon GloboCare (ALBT), this balance is critical when scaling innovations. An optimal value ensures sustainable development without the risk of default. The long-term debt-to-equity history clearly demonstrates this financial strategy.